Mesothelioma treatment: are we on target : a review
- Author
- Birgitta I Hiddinga, Christian Rolfo and Jan Van Meerbeeck (UGent)
- Organization
- Keywords
- GROWTH-FACTOR, LUNG-CANCER, PHASE-II TRIAL, LEUKEMIA GROUP-B, MALIGNANT-PLEURAL-MESOTHELIOMA, Biomarker, Mesothelin, Biological treatment, Targeted therapy, Malignant pleural mesothelioma, ARGININOSUCCINATE SYNTHETASE, OPEN-LABEL, EUROPEAN-ORGANIZATION, PLUS BEVACIZUMAB, CLINICAL-TRIAL
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 791.69 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-7071576
- MLA
- Hiddinga, Birgitta I., et al. “Mesothelioma Treatment: Are We on Target : A Review.” JOURNAL OF ADVANCED RESEARCH, vol. 6, no. 3, 2015, pp. 319–30, doi:10.1016/j.jare.2014.11.012.
- APA
- Hiddinga, B. I., Rolfo, C., & Van Meerbeeck, J. (2015). Mesothelioma treatment: are we on target : a review. JOURNAL OF ADVANCED RESEARCH, 6(3), 319–330. https://doi.org/10.1016/j.jare.2014.11.012
- Chicago author-date
- Hiddinga, Birgitta I, Christian Rolfo, and Jan Van Meerbeeck. 2015. “Mesothelioma Treatment: Are We on Target : A Review.” JOURNAL OF ADVANCED RESEARCH 6 (3): 319–30. https://doi.org/10.1016/j.jare.2014.11.012.
- Chicago author-date (all authors)
- Hiddinga, Birgitta I, Christian Rolfo, and Jan Van Meerbeeck. 2015. “Mesothelioma Treatment: Are We on Target : A Review.” JOURNAL OF ADVANCED RESEARCH 6 (3): 319–330. doi:10.1016/j.jare.2014.11.012.
- Vancouver
- 1.Hiddinga BI, Rolfo C, Van Meerbeeck J. Mesothelioma treatment: are we on target : a review. JOURNAL OF ADVANCED RESEARCH. 2015;6(3):319–30.
- IEEE
- [1]B. I. Hiddinga, C. Rolfo, and J. Van Meerbeeck, “Mesothelioma treatment: are we on target : a review,” JOURNAL OF ADVANCED RESEARCH, vol. 6, no. 3, pp. 319–330, 2015.
@article{7071576,
author = {{Hiddinga, Birgitta I and Rolfo, Christian and Van Meerbeeck, Jan}},
issn = {{2090-1232}},
journal = {{JOURNAL OF ADVANCED RESEARCH}},
keywords = {{GROWTH-FACTOR,LUNG-CANCER,PHASE-II TRIAL,LEUKEMIA GROUP-B,MALIGNANT-PLEURAL-MESOTHELIOMA,Biomarker,Mesothelin,Biological treatment,Targeted therapy,Malignant pleural mesothelioma,ARGININOSUCCINATE SYNTHETASE,OPEN-LABEL,EUROPEAN-ORGANIZATION,PLUS BEVACIZUMAB,CLINICAL-TRIAL}},
language = {{eng}},
number = {{3}},
pages = {{319--330}},
title = {{Mesothelioma treatment: are we on target : a review}},
url = {{http://doi.org/10.1016/j.jare.2014.11.012}},
volume = {{6}},
year = {{2015}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: